Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. chief financial officer Michael Burkes Brophy reported two stock transactions. On March 9, 2026, he received 1,968 fully vested RSUs, each representing one share of common stock, as a stock award with no cash paid per share.
On March 10, 2026, he sold 785 shares of common stock at $204.1327 per share to cover tax withholding and remittance obligations related to the RSU vesting, under written instructions intended to satisfy Rule 10b5-1(c). After these transactions, he directly held 63,354 shares of Natera common stock.
Natera, Inc. CEO and president Steven Leonard Chapman reported a compensation-related share grant and a linked sale. On March 9, 2026, he received 5,623 fully vested Restricted Stock Units (RSUs), each representing one share of common stock. On March 10, 2026, he executed an open-market sale of 5,623 shares at an average price of $204.1327 per share, with the sale described as being partially to satisfy tax withholding obligations and carried out under a written instruction intended to meet Rule 10b5-1(c) conditions. After these transactions, he directly holds 156,607 shares of Natera common stock.
Natera, Inc. executive Daniel Rabinowitz, the Secretary and Chief Legal Officer, reported routine equity compensation activity and related share sales. He received a fully vested grant of 1,745 Restricted Stock Units, each representing one share of common stock. The next day, he sold 1,745 common shares in an open-market transaction at an average price of $204.1327 per share, leaving him with 233,285 shares of common stock held directly after the sale.
According to the disclosure, the sale was partially conducted to cover tax withholding and remittance obligations tied to the RSU vesting and was executed under written instructions intended to qualify for the Rule 10b5-1(c) affirmative defense, indicating a pre-arranged trading framework rather than an opportunistic trade.
Natera, Inc. director and co-founder Sheena Jonathan reported a small mix of stock compensation and related tax selling. On March 9, 2026, she received 258 shares of Common Stock as fully vested Restricted Stock Units granted at $0.0000 per share.
On March 10, 2026, she sold 127 shares of Common Stock at an average price of $204.1327 per share. The filing states this sale was made to satisfy tax withholding and remittance obligations tied to the RSU vesting and was executed under written instructions intended to qualify under Rule 10b5‑1. After these transactions, she directly owned 262,325 shares of Common Stock, with additional shares held in Caraluna 1 Trust and Caraluna 2 Trust for which she disclaims beneficial ownership.
Natera, Inc. reported that its president and chief business officer, John Fesko, received a grant of 1,774 fully vested restricted stock units (RSUs), each representing one share of common stock. These RSUs were issued as a stock award with no cash price per share.
On the following day, Fesko executed an open-market sale of 707 shares of common stock at $204.1327 per share. According to the footnotes, this sale was carried out to satisfy tax withholding and remittance obligations related to the RSU vesting and was made pursuant to written instructions intended to meet Rule 10b5-1(c) conditions. After these transactions, Fesko directly held 189,199 shares of Natera common stock.
Natera, Inc. president of clinical diagnostics Solomon Moshkevich reported compensation-related stock activity. He received 1,774 fully vested Restricted Stock Units (RSUs), each representing the right to one share of Natera common stock. The next day, he sold 915 shares of common stock at $204.1327 per share.
The sale was carried out to satisfy tax withholding and remittance obligations arising from the RSU vesting and was made under a written instruction intended to meet the Rule 10b5-1(c) affirmative defense conditions in his March 9, 2026 stock unit agreement. After these transactions, he directly held 150,882 shares of Natera common stock.
Natera, Inc. executive Daniel Rabinowitz, the Secretary and Chief Legal Officer, exercised options to acquire 5,598 shares of common stock at an exercise price of $19.68 per share. These options were fully exercisable.
On the same date, he sold a total of 8,398 shares of Natera common stock in open-market transactions at weighted-average prices disclosed between $193.27 and $198.32 per share, pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025. After these transactions, he continued to hold 233,285 shares of Natera common stock directly.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice concerning proposed sales of common shares of the issuer. The filing lists multiple recent dispositions by Daniel Rabinowitz, including 19,234 shares for $4,514,958.39 on 01/20/2026 and 1,334 shares for $307,844.51 on 02/03/2026.
Natera, Inc. director and co-founder Jonathan Sheena reported mixed equity activity in Natera stock. On March 2, 2026, he completed open-market sales totaling 3,070 shares of Common Stock at weighted average prices ranging from $198.24 to $202.85 per share under a pre-arranged Rule 10b5-1 trading plan adopted on June 7, 2024. Following these sales, his directly held stake reported in this filing was 262,194 shares.
On February 27, 2026, Sheena also received a grant of 2,103 Restricted Stock Units (RSUs), each representing a contingent right to one share of Common Stock. The RSUs vest over four years, with 25% vesting on March 1, 2027 and the rest in 12 equal quarterly installments. The filing also notes indirect holdings in trusts for beneficiaries, for which he disclaims beneficial ownership.
Natera, Inc. director and CEO Steven Leonard Chapman reported both an equity award and share sales. On February 27, 2026, he received 37,401 Restricted Stock Units (RSUs), which vest over four years starting March 1, 2027, with each RSU representing one common share. On March 2, 2026, he sold a total of 3,950 shares of common stock in three open-market transactions at weighted average prices around $199–$201 per share, executed under a pre-established Rule 10b5-1 trading plan adopted December 11, 2023 and amended December 2, 2024. Following these transactions, he directly held 156,607 common shares.